Now Enrolling, Learn How You Can Refer Patients

Many of the estimated 4 to 12 million people in the U.S. who suffer from the pain and life interruption of IC/BPS may be seeking new pain management treatments.

A phase 2 clinical study will evaluate IW-3300, a novel, rectally administered foam treatment with a direct, innovative mechanism of action that may reduce pain associated with IC/BPS. Based upon phase 1 study data, IW-3300 appears to be well tolerated.

Basic criteria for potential study participants include:         

  • Ages 18–70
  • Chronic bladder pain for the past six months or more associated with filling the bladder



About the Study

Key Eligibility Criteria

How to Become an Investigator

How to Refer Patients


To see how you can get involved by referring a patient, click here to learn more.